Search

Displaying results 4831 - 4840 of 5048 in total
  1. Drug

    Epcoritamab

    go.drugbank.com/drugs/DB16672
    ApprovedInvestigational

    [L46516,L46556] In September 2023, epcoritamab was also approved in the EU for the same indication.

  2. Drug

    Cantharidin

    go.drugbank.com/drugs/DB12328
    ApprovedInvestigational

    [A32891, A32892] Topical cantharidin products do not necessarily demonstrate any particular better effectiveness at treating topical skin conditions like warts than other commonly available vesicant

  3. Drug

    TGAAC94

    go.drugbank.com/drugs/DB06175
    Investigational

    The Health Recombinant DNA Advisory Committee (RAC) concluded that a possible role of the gene transfer in this clinical course could not definitively be excluded due to the lack of data. [A264038]

  4. Drug

    Eliapixant

    go.drugbank.com/drugs/DB21465
    Investigational

    Eliapixant has a monoisotopic molecular weight of 478.13 Da.

  5. Drug

    Oxycodegol

    go.drugbank.com/drugs/DB14146
    Investigational

    The lack of abuse potential is believed to be due to the drug's slow rate of entry into brain, a unique characteristic compared to others in the opioid class [A33997, A34016].

  6. Drug

    Tegoprazan

    go.drugbank.com/drugs/DB16690
    Investigational

    [A234215, A234220] Tegoprazan’s strong and sustained effect is due to its ability to be slowly cleared from the gastric glands and exertion of effects independent of acid levels.

  7. Drug

    Casimersen

    go.drugbank.com/drugs/DB14984
    ApprovedInvestigational

    Although corticosteroids effectively slow disease progression in both DMD and BMD patients, they do not address the underlying molecular pathogenesis.

  8. Drug

    Vilanterol

    go.drugbank.com/drugs/DB09082
    ApprovedInvestigational

    [A7737] This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug administration).

  9. Drug

    Pegvaliase

    go.drugbank.com/drugs/DB12839
    ApprovedInvestigational

    [L42725] It is advantageous over currently available management therapies for PKU, such as [DB00360], that are ineffective to many patients due to long-term adherence issues or inadequate Phe-lowering

  10. Drug

    Betibeglogene autotemcel

    go.drugbank.com/drugs/DB16900
    ApprovedInvestigational

    A251770] Allogeneic hematopoietic-cell transplantation would be a therapeutic option in patients with β-thalassemia; however, this process is reserved for young children with an HLA-identical sibling donor due